A phase i trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: A cancer research UK study

Clinical Cancer Research

Volumn 21, Issue 2, 2015, Pages 267-273

  Moreno, Lucas ^a,b   Marshall, Lynley V ^a,c   Pearson, Andrew D J ^a,c   Morland, Bruce ^d   Elliott, Martin ^e   Campbell Hewson, Quentin ^f   Makin, Guy ^g   Halford, Sarah E R ^h   Acton, Gary ^h   Ross, Philip ^h   Kazmi Stokes, Shamim ^h   Lock, Victoria ⁱ   Rodriguez, Ana ⁱ   Lyons, John F ⁱ   Boddy, Alan V ^j   Griffin, Melanie J ^j   Yule, Murray ⁱ   Hargrave, Darren ^k  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Structural Biology and Biocomputing Programme   (Spain)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

^f Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

ⁱ ASTEX PHARMACEUTICALS   (United Kingdom)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

^k GREAT ORMOND STREET HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; ALANINE AMINOTRANSFERASE; AURORA B KINASE; KI 67 ANTIGEN; 1-CYCLOPROPYL-3-(3-(5-MORPHOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL)UREA; ANTINEOPLASTIC AGENT; AURORA KINASE; BENZIMIDAZOLE DERIVATIVE; UREA;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPOPHOSPHATEMIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RASH; SKIN BIOPSY; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UNITED KINGDOM; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; MAXIMUM TOLERATED DOSE; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; AURORA KINASES; BENZIMIDAZOLES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; TREATMENT OUTCOME; UREA;

EID: 84920983167     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1592     Document Type: Article

References (23)

1. Cancer Research UK. Childhood cancer mortality statistics. London: Cancer Research UK; 2010 [cited 2014 03 March 2014]; Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/childhoodcancer/mortality/#Main.
2. Moore AS, Blagg J, Linardopoulos S, Pearson AD. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010;24:671-8.
3. Hilton JF, Shapiro GI. Aurora kinase inhibition as an anticancer strategy. J Clin Oncol 2014;32:57-9.
4. Goodwin R, Giaccone G, Calvert H, Lobbezoo M, Eisenhauer EA. Targeted agents: how to select the winners in preclinical and early clinical studies? Eur J Cancer 2012;48:170-8.
5. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuro blastoma. Cancer Cell 2009;15:67-78.
6. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55:26-34.
7. Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, et al. The aurora kinase inhibitor CCT137690 down regulates MYCN and sensitizes MYCN-amplified neuro blastoma in vivo. Mol Cancer Ther 2011;10:2115-23.
8. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors- rising stars in cancer therapeutics? Mol Cancer Ther 2010;9:268-78.
9. Buczkowicz P, Zarghooni M, Bartels U, Morrison A, Misuraca KL, Chan T, et al. Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma. Brain Pathol 2013;23:244-53.
10. Lehman NL, O'Donnell JP, Whiteley LJ, Stapp RT, Lehman TD, Roszka KM, et al. Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle 2012;11:489-502.
11. Foran JM, Ravandi F, O'Brien SM, Borthakur G, Rios M, Boone P, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. J Clin Oncol 2010;26:2528.
12. Kristeleit R, Calvert H, Arkenau H, Olmos D, Adam J, Plummer ER, et al. A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol 2009;27:2566.
13. Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multi targeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-88.
14. Santo L, Hideshima T, Cirstea D, Bandi ML, Nelson EA, Ikeda H, et al. AT9283, a small molecule multi-targeted kinase inhibitor with potent activity against aurora kinase and STAT3 in combination with lenalidomide results in synergistic anti-myeloma activity. Am Soc Hematol 2010; Abstract 2994.
15. Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2012;23:1307-13.
16. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10:514-23.
17. Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC. Shortening the timeline of pediatric phase I trials: The rolling six design. J Clin Oncol 2008;26:190-5.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
19. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuro blastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
20. Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, et al. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle 2009;8:1921-9.
21. Mosse YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel B, et al. Pediatric phase I trial and pharmacokinetic study ofMLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: A Children's Oncology Group Phase I Consortium study. Clin Cancer Res 2012;18:6058-64.
22. Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014;32:44-50.
23. Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 2011;118:6030-6.